QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)
QQQ   386.32 (-0.93%)
AAPL   189.43 (-0.95%)
MSFT   369.14 (-1.43%)
META   320.02 (-1.48%)
GOOGL   129.27 (-1.96%)
AMZN   144.84 (-1.49%)
TSLA   235.58 (-1.36%)
NVDA   455.10 (-2.68%)
NIO   7.32 (+2.38%)
BABA   73.03 (-1.30%)
AMD   118.57 (-2.32%)
T   16.67 (-0.60%)
F   10.70 (+1.13%)
MU   74.29 (-2.16%)
CGC   0.76 (+22.72%)
GE   121.50 (-0.82%)
DIS   92.01 (-0.62%)
AMC   7.50 (+9.18%)
PFE   29.25 (+1.18%)
PYPL   59.85 (+0.34%)
XOM   102.43 (-0.54%)

Sosei Group Stock Price, News & Analysis (OTCMKTS:SOLTF)

$9.48
-0.47 (-4.72%)
(As of 12/4/2023 ET)
Compare
Today's Range
$9.48
▼
$9.71
50-Day Range
$8.93
▼
$10.41
52-Week Range
$8.93
▼
$22.78
Volume
1,100 shs
Average Volume
1,582 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock AnalysisAnalyst ForecastsChartHeadlinesShort Interest

SOLTF stock logo

About Sosei Group Stock (OTCMKTS:SOLTF)

Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of GPR35 agonist, for inflammatory bowel disease/GI disorders, which is in preclinical stage; HTL0016878 for Schizophrenia and other neuropsychiatric disorders; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; and PF-07258669 for anorexia. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, Neurocrine Biosciences, Novartis, Verily, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.

SOLTF Stock Price History

SOLTF Stock News Headlines

November 24, 2023 | finance.yahoo.com
Sosei Heptares to Regain Full Ownership of GSK4381406*, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease
November 14, 2023 | morningstar.com
Sosei Group Corp 4565
December 4, 2023 | Wealthpress (Ad)
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
November 10, 2023 | msn.com
Sosei Group reports Q3 results
November 10, 2023 | finance.yahoo.com
Sosei Heptares and Kallyope Nominate First GPCR Target for Therapeutic Development in Gastrointestinal Diseases
November 10, 2023 | finance.yahoo.com
Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2023
November 7, 2023 | finance.yahoo.com
Sosei Heptares’ President & CEO and Head of UK R&D to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2023
November 5, 2023 | finance.yahoo.com
Sosei Heptares’ Partner, Pfizer, Progresses Its GLP-1 Receptor Agonist PF-06954522 into a Phase 1 Trial
December 4, 2023 | Wealthpress (Ad)
Trading Experts Call It “The Perfect Tesla Trade”
Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.
October 31, 2023 | finance.yahoo.com
Sosei Heptares Announces Submission of New Drug Application in Japan for Daridorexant (ACT-541468), a Dual Orexin Receptor Antagonist for the Treatment of Insomnia
October 31, 2023 | finance.yahoo.com
Sosei Heptares Will Receive US$3.75 Million Payment in Multi-Target Partnership
October 25, 2023 | finance.yahoo.com
Sosei Heptares to Host R&D Day Highlighting its Innovative R&D and Late-Stage Development Progress
October 18, 2023 | finance.yahoo.com
Sosei Heptares’ President & CEO Chris Cargill Wins Executive of the Year at the Citeline Pharma Intelligence Awards Japan 2023
October 10, 2023 | msn.com
Sosei and PharmEnable collaborate on another neurological drug
October 4, 2023 | finance.yahoo.com
Sosei Heptares and Verily Nominate First G-protein-coupled receptor Target for Therapeutic Development
September 20, 2023 | finance.yahoo.com
Sosei Heptares Adds World-leading Expertise to its Scientific Advisory Board
August 10, 2023 | finance.yahoo.com
Sosei Heptares and Cancer Research UK Announce the Dosing of the First Patient in a Phase I/IIa Trial with Cancer Immunotherapy Drug HTL0039732
August 4, 2023 | finance.yahoo.com
Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2023
July 21, 2023 | reuters.com
Sosei buys Idorsia Pharmaceuticals' Japan, Korea units for $466 million - Nikkei
June 27, 2023 | marketwatch.com
Sosei Group Shares Indicated Lower After Partner Pfizer Terminates Diabetes Drug Development
June 3, 2023 | msn.com
Sosei Group (TYO:4565) Price Target Increased by 5.50% to 3,351.43
April 5, 2023 | finance.yahoo.com
Sosei Heptares Confirms Changes to its Board and Executive Management Team at Annual Shareholders’ Meeting
March 18, 2023 | finance.yahoo.com
Sosei Heptares Receives Approval for Change of Market Listing Segment to the Tokyo Stock Exchange Prime Market
December 22, 2022 | reuters.com
Sosei Group Corp
November 8, 2022 | finance.yahoo.com
PrecisionLife to Evaluate Precision Medicine Potential of Sosei Heptares Neuroscience GPCR Target
September 17, 2022 | investing.com
Sosei Group Corp (4565)
September 13, 2022 | msn.com
EXCLUSIVE | Ola Electric rejigs roles to unify operations across roles; YS Kim gets larger role
See More Headlines
Receive SOLTF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sosei Group and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:SOLTF
CUSIP
N/A
CIK
N/A
Web
www.sosei.com
Phone
(135) 210-3290
Fax
N/A
Employees
348
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
N/A
The Best High-Yield Dividend Stocks for 2023 Cover
The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Shinichi Tamura (Age 74)
    Founder & Chairman of the Board
    Comp: $1.54M
  • Mr. Christopher Cargill (Age 39)
    Representative Executive Officer, President, CEO & Director
    Comp: $1.32M
  • Mr. Hironoshin Nomura (Age 40)
    Executive Officer, Executive VP & CFO
  • Mr. Kieran Johnson F.C.A. (Age 54)
    Executive Officer, Executive VP & Chief Accounting Officer
  • Dr. Miles Congreve
    Chief Scientific Officer
  • Mr. Kazuhiko Yoshizumi (Age 69)
    Executive Officer, Executive VP & Chief Compliance Officer
  • Shinichiro Nishishita
    VP of Investor Relations & Head of Regulatory Disclosures
  • Stacey Southall
    Associate Director & Head of Biophysics
  • Ms. Candelle Chong (Age 34)
    Executive Officer, Executive VP & Chief of Staff
  • Dr. Satoshi Tanaka
    Executive Officer, Executive VP & President of Idorsia Pharmaceuticals Japan

Key Competitors

View All Competitors














SOLTF Stock Analysis - Frequently Asked Questions

Should I buy or sell Sosei Group stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sosei Group in the last twelve months. There are currently 2 sell ratings for the stock. The consensus among Wall Street analysts is that investors should "sell" SOLTF shares.
View SOLTF analyst ratings or view top-rated stocks.

How have SOLTF shares performed in 2023?

Sosei Group's stock was trading at $15.5439 at the start of the year. Since then, SOLTF shares have decreased by 39.0% and is now trading at $9.48.
View the best growth stocks for 2023 here.

Are investors shorting Sosei Group?

Sosei Group saw a decline in short interest in November. As of November 15th, there was short interest totaling 1,062,100 shares, a decline of 29.0% from the October 31st total of 1,495,200 shares. Based on an average daily volume of 200 shares, the days-to-cover ratio is currently 5,310.5 days.
View Sosei Group's Short Interest.

How do I buy shares of Sosei Group?

Shares of SOLTF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:SOLTF) was last updated on 12/4/2023 by MarketBeat.com Staff

My Account -